Target- |
Mechanism- |
|
|
|
Inactive Indication- |
Drug Highest PhaseClinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
/ Not yet recruitingNot Applicable 以安慰剂为对照评价三味骨伤胶囊治疗骨折(气滞血瘀证)后肿痛的有效性和安全性的随机、双盲、多中心研究
[Translation] A randomized, double-blind, multicenter study to evaluate the efficacy and safety of Sanwei Gushang Capsule in the treatment of post-fracture swelling and pain (Qi stagnation and blood stasis syndrome) with placebo as control
1.进一步评价三味骨伤胶囊治疗骨折(气滞血瘀证)后肿痛的临床疗效。
2.进一步评价三味骨伤胶囊临床应用的安全性。
[Translation] 1. To further evaluate the clinical efficacy of Sanwei Gushang Capsule in treating swelling and pain after fracture (Qi stagnation and blood stasis syndrome).
2. To further evaluate the safety of Sanwei Gushang Capsule in clinical application.
100 Clinical Results associated with Gansu Heihong Pharmaceutical Co., Ltd.
0 Patents (Medical) associated with Gansu Heihong Pharmaceutical Co., Ltd.
100 Deals associated with Gansu Heihong Pharmaceutical Co., Ltd.
100 Translational Medicine associated with Gansu Heihong Pharmaceutical Co., Ltd.